Previous 10 | Next 10 |
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2...
Deciphera Pharmaceuticals (NASDAQ: DCPH) , a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -...
Deciphera Receives FDA Approval for GIST Therapy Deciphera Pharmaceuticals ( DCPH ) reported that it has received an early FDA approval for Qinlock for treating patients with gastrointestinal stromal tumor (GIST). The treatment is specifically targeted at patients who did not response to...
-QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in INVICTUS Phase 3 Study- -NDA Approved 3 Months Prior to Action Date Under FDA’s Real Time Oncology Review (RTOR)- -Deciphera to Host Conference Call Today at 5:0...
The FDA approves Deciphera Pharmaceuticals' ( DCPH +6.7% ) ripretinib, branded as Qinlock, for the fourth-line treatment of gastrointestinal stromal tumor (GIST). More news on: Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Nasdaq has suspended trading in Deciphera Pharmaceuticals ( DCPH +6.6% ) pending the release of news. More news on: Deciphera Pharmaceuticals, Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, Read more ...
Blueprint Medicines (NASDAQ: BPMC ) reports that it has received a Complete Response Letter (CRL) from the FDA regarding its marketing application for avapritinib in fourth-line gastrointestinal tumor (GIST). More news on: Blueprint Medicines Corporation, Bayer Aktiengesellschaft, Deciph...
Deciphera Pharmaceuticals Inc (DCPH) Q1 2020 Earnings Conference Call May 5, 2020 16:30 ET Company Participants Jen Robinson - Vice President, Investor Relations Steve Hoerter - President and Chief Executive Officer Matt Sherman - Chief Medical Officer Dan Martin - Chief Commer...
Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q1 2020 Earnings Call May 5, 2020 , 4:30 p.m. ET Operator Continue reading
Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q1 GAAP EPS of -$1.36 misses by $0.05 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to th...